Negotiations between MSD and Revolution Medicines over a possible takeover – estimated to have been potentially worth up to $30 billion – have reportedly ended without agreement. That is according to ...

The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD candidates with blockbuster potential. According to Reuters, MSD – known as Merck & Co in ...